WilliamKennedyMD
Pediatrics • San Francisco, CAPediatric Infectious Disease
Senior Vice President Clinical Development
Dr. Kennedy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
499 Jackson St
suite 300
San Francisco, CA 94111
Summary
- Pediatric Infectious Diseases - academic training and clinical experience.
Clinical Researcher, small, large molecule platforms and gene therapy with biologics, in pharmaceutical industry. Key contributor to development and launch of the sedative "Belsomra" or suvorexant (orexin antagonist).
Academic biochemist and structural biologist in macromolecular crystallography and 3D NMR spectroscopy.
Education & Training
Yale-New Haven Medical CenterFellowship, Pediatric Infectious Diseases, 1998 - 2001
Duke University HospitalInternship, Transitional Year, 1992 - 1993
Stanford University School of MedicineClass of 1992
Certifications & Licensure
CT State Medical License 2001 - 2026
TX State Medical License 2005 - 2026
Clinical Trials
- Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers Start of enrollment: 2017 Jan 31
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Start of enrollment: 2009 Sep 01
- Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART Start of enrollment: 2022 Jan 24
- Join now to see all
Publications & Presentations
PubMed
- 25 citationsAssessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.Kerri A. Schoedel, Hong Sun, Edward M. Sellers, Janice Faulknor, Naama Levy-Cooperman
Journal of Clinical Psychopharmacology. 2016-08-01 - 97 citationsIn Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tra...Eric D. Hostetler, Aniket D. Joshi, Sandra Sanabria-Bohorquez, Hong Fan, Zhizhen Zeng
The Journal of Pharmacology and Experimental Therapeutics. 2013-11-01 - 117 citationsEffects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.Hong Sun, William P. Kennedy, Darren Wilbraham, Nicole Lewis, Nicole Calder
Sleep. 2013-02-01
Authored Content
- Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover StudyAugust 2016
Press Mentions
Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical DevelopmentApril 2nd, 2021
Grant Support
- Phase 1 Clinical Research Program for Functional Cure of HIV with in vivo Gene TherapyCalifornia Institute of Regenerative Medicine2022–2026
Research History
- Senior Vice President, clinical development at Excision BiotherapeuticsHIV cure paradigm using CRISPRCas9 genome excision of provirus HIV12021 - 2026
Professional Memberships
- International AIDS SocietyMember
- American Society of Gene and Cell TherapyMember
- European Society Gene and Cell TherapyMember
Industry Relationships
- Senior Vice President, Excision BiotherapeuticsFunctional cure of latent infectious diseases with CRISPR-SaCas9 [HIV, HBV, HSV]Disclosure: Excision Biotherapeutics- current2021 - Present
External Links
- ClinicalTrials.govhttps://clinicaltrials.gov/
- EBT-101https://clinicaltrials.gov/ct2/show/NCT05144386?term=EBT-101&draw=2&rank=1
- This is a FIH, open-label, sequential cohort, single ascending dose (SAD) study of EBT-101[CRISPR] for potential functional cure of HIV-1 subgroup B infected adults.https://clinicaltrials.gov/ct2/show/NCT05144386?term=EBT-101&draw=2&rank=1
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
